- Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
- Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 Million
- Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild Offering
- Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023
- Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023
- Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting
- Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023
- Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease
More ▼
Key statistics
On Thursday, Vivoryon Therapeutics NV (VVY:AEX) closed at 14.20, -27.40% below its 52-week high of 19.56, set on May 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.64 |
---|---|
High | 14.70 |
Low | 13.98 |
Bid | 13.90 |
Offer | 14.90 |
Previous close | 14.64 |
Average volume | 78.64k |
---|---|
Shares outstanding | 25.89m |
Free float | 17.82m |
P/E (TTM) | -- |
Market cap | 379.04m EUR |
EPS (TTM) | -1.28 EUR |
Data delayed at least 15 minutes, as of Jun 01 2023 16:35 BST.
More ▼